[April 14, 2014]

Research and Markets: Japan Schizophrenia Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/v77gdj/pharmapoint) has announced the addition of the "PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

The youth of Japan's schizophrenia drug market will drive a significant period of growth over the forecast period. Disease management in Japan uses LAIs less often than the countries in the EU, and the US as well. However, their growing role in schizophrenia treatment is driving a growing popularity in Japan, and the uptake of new LAI therapies should be rapid.

Scope

• Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Japan from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the Japan Schizophrenia market.

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

• Etiology
• Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

• Subjective Assessments
• Disease Subtypes

4.2 Treatment Overview

• Treatment of Acute Agitation Associated with Schizophrenia
• Maintenance Treatment of Schizophrenia

4.3 Japan

• Diagnosis
• Clinical Practice

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

5.3 Product Profiles by Generation

Conventional Antipsychotics

Atypical Antipsychotics

6 Opportunity and Unmet Need

6.1 Unmet Needs Overview

• Public Awareness
• Early Diagnosis and Treatment
• Long-Acting and Advanced Drug Delivery Systems
• Effective Management of Negative and Cognitive Symptom Domains

6.2 Gap Analysis

• Long-Acting Drug Delivery
• Treatment of Negative and Cognitive Symptoms

7 Pipeline Assessment

7.1 Overview

7.2 Early-Stage Pipeline Assessment

7.3 Novel Therapeutic Approaches

• Negative Symptoms
• Cognitive Symptoms

7.4 Long-Acting Drug Delivery

7.5 Technology Trends Analysis

7.6 Key Drugs in Clinical Development

• Aripiprazole Lauroxil
• Cariprazine
• Brexpiprazole
• Zicronapine
• Bitopertin
• EVP-6124

8 Market Outlook

8.1 Japan

• Forecast
• Key Events
• Drivers and Barriers

9 Appendix

Visit http://www.researchandmarkets.com/research/v77gdj/pharmapoint

[ Back To TMCnet.com's Homepage ]